influenza virus entry

MBX2329 是一种流感病毒抑制剂，能特异性地抑制血凝素介导的病毒进入，HIV/HA(H5) 的 IC90值为8.6 μM。它能够有效地抑制多种甲型流感病毒。

CBS1117 是一种病毒进入抑制剂，对甲型流感病毒 A/Puerto Rico/8/34 的 IC50为 70 nM。它干扰血凝素介导的融合过程。

IAV-IN-2 (Compound MC-22) 抑制甲型流感病毒 (IAV) 通过网格蛋白介导的内吞作用 (CME) 侵入宿主细胞。

CL385319 is a potent inhibitor of H5N1 avian influenza A virus infection by blocking viral entry. CL-385319 is effective in inhibiting infection of highly pathogenic H5N1 influenza A virus in Madin-Darby Canine Kidney (MDCK) cells with an IC50 of 27.03±2.

CAY10766 is an antiviral compound.1It inhibits entry of influenza virus-like particles pseudotyped with hemagglutinin A (HA) from H5N1 influenza A virus into A549 cells (EC50= 0.24 μM). CAY10766 (1 μM) reduces H1N1 and H5N1 influenza A viral titers in infected MDCK cells. It also exhibits synergy with oseltamivir carboxylate in MDCK cells infected with the influenza A reporter PR8-NS1-Gluc virus.

Ribavirin-13C5 is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin (T0684) is an antiviral guanosine nucleoside analog.1,2Upon entry into cells,ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg)reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV),hepatitis C virus (HCV),and viral hemorrhagic fevers.

RSV/IAV-IN-3 (compound 14'i) 是一种双重的呼吸道合胞病毒 (RSV) (EC50: 2.92 μM) 和甲型流感病毒 (IAV) (EC50: 1.90 μM) 的双重抑制剂。RSV/IAV-IN-3 对 H1N1 和 H3N2 表现出抗病毒作用，在 MDCK 细胞中的 EC50值分别为 3.25 μM 和 1.50 μM。RSV/IAV-IN-3 能够剂量依赖性地明显抑制荧光素酶的活性 (EC50: 3.89 μM)。RSV/IAV-IN-3 可以抑制 IAV 感染和 RdRp 活性，在进入后阶段抑制 IAV 和 RSV 复制。

Gedivumab（MHAA4549A；RG7745）是一种人源单克隆抗体，可通过结合流感 A 病毒血凝素蛋白高度保守的茎部区域而特异性靶向流感 A 病毒。Gedivumab 可阻断血凝素成熟并抑制病毒进入过程中膜融合步骤，被广泛应用于流感 A 病毒感染机制及抗病毒治疗研究。

Antiviralagent 43 (compound 16)，一种口服活性甲型流感病毒 (influenza A viruses) 侵入抑制剂，有效抑制VH04-H5N1和PR8-H1N1甲型流感病毒株复制，其EC50分别为240 nM与72 nM。

MI-1904 是一种针对matriptase/TMPRSS2的抑制剂,能有效对抗流感病毒 (influenza virus) H1N1 和 H9N2,并展示出抗病毒活性.该化合物通过阻断病毒表面糖蛋白的裂解,避免病毒与宿主细胞受体的结合,进而抑制病毒的侵入和复制过程.